The only successful phase II vaccine clinical trial against HIV used a recombinant virus triggering envelope proteins (RV144), and demonstrated an efficacy of about 30 % at preventing HIV infection [27]. This evidence concerns the gene ERVW-1 and HIV infectious disease.